An observational study in Artificial Intelligence and Retinal Diseases, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 1 Year to 100 Years. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by Beijing Tongren Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Retinal Diseases with a site in China — 12 open to participants now, 14 under way, 1 of them phase 3. Retinal Diseases · China.
Among the 29 studies in Retinal Diseases with a site in China, this one is the 2nd largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2023, is one of 17 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 18th registered.
333 studies on the registry are indexed under Retinal Diseases; 59 are open to participants now.
Browse Retinal Diseases studies →12 of the 29 studies in Retinal Diseases with a site in China are open now. Recruiting first, the newest first:
Dan Chen · Sites in China
Ages 3+
InnoVec Biotherapeutics Inc. · Sites in China
Ages 50+
VeonGen Therapeutics GmbH · Sites in China
Ages 6+
Beijing Tongren Hospital · Sites in China
Ages 50–75
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 44 Retinal Diseases studies recruiting now, 30 (68%) set no upper age limit and 4 (9%) stop at 75 or younger; 16 take children under 18; 19 take healthy volunteers.
This study: 1 Year to 100 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 1
First in 2010; this study’s year is marked. 3 started in 2023.
This study's planned enrollment of 100,000 is above the median of 200 across 118 observational studies indexed under Retinal Diseases.
Median enrollment 35 across the 11 interventional studies, 2,000 across the 17 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
Beijing Tongren Hospital is the lead sponsor of 165 studies on the registry; 54 are open to participants now.
Beijing Tongren Hospital has 4 studies filed under Retinal Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Retinal Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to apply an artificial intelligence algorithm to diagnose multi-retinal diseases in real-world settings. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, and area under curve.
The objective of this study is to apply an artificial intelligence algorithm to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography. tic 45-degree fundus cameras, trained operators took binocular fundus photography on participants. Operators were then asked to identify gradable images and unload for algorithm diagnosis. The effectiveness and accuracy of this algorithm are evaluated by sensitivity, specificity, positive predictive value, negative predictive value, area under curve, and F1 score.
The study population is derived from an anonymous database that contains health examination results of the general population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
An artificial intelligence algorithm was applied to diagnose referral diabetes retinopathy, referral age-related macular degeneration, referral possible glaucoma, pathological myopia, retinal vein occlusion, macular hole, macular epiretinal membrane, hypertensive retinopathy, myelinated fibers, retinitis pigmentosa and other retinal lesions from fundus photography.
Diagnostic Test: artificial intelligence algorithm
Retinal diseases diagnosed by artificial intelligence algorithm
Area under curve
We used the receiver operating characteristic (ROC) curve and area under curve to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.
Time frame: 1 month
Sensitivity and specificity
We used sensitivity and specificity to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.
Time frame: 1 month
Positive predictive value, negative predictive value
We used positive predictive value and negative predictive value to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.
Time frame: 1 month
F1 score
We used F1 score to examine the ability of this artificial intelligence algorism recognition and classification of retinal diseases.
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Aug 2028, 60 months after the start.
Of 54 observational studies under Retinal Diseases, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 17. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.